News

Cheaper Chinese HPV Vaccines Turn Merck’s Gardasil From Boom to Bust
On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...
Investor's Business Daily on MSN19h
Gardasil Sales Decline — Again. Can Dow Jones Stock Merck Take The Hit?
Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, ...
BioSpace1d
Sales of Merck’s 4-Way Measles Vaccine Take Hit as US Dips Into Stockpile
Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.
Health Care Roundup: Market Talk
Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.
Merck posts higher profit, puts tariffs cost at $200 million
Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...
Merck highlights $9B manufacturing investment through 2028 as Q1 2025 revenues reach $15.5B
Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...
News Medical24d
Gardasil 9
GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.
Merck Announces First-Quarter 2025 Financial Results
Total Worldwide Sales Were $15.5 Billion, a Decrease of 2% From First Quarter 2024; Excluding the Impact of Foreign Exchange, ...
Merck Q1 Earnings Preview: What to expect?
In the last two years, Merck has beaten EPS estimates 88% of the time, and revenue estimates 100% of the time. Meanwhile, ...
GlobalData on MSN22h
MSD’s Gardasil sales slide further due to China constraints
MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.